Tarbox Family Office, Inc. Incyte Corp Transaction History

Tarbox Family Office, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 25, 2022	SELL	$66.02 - $79.71 $4,489 - $5,420	-68 Closed	0 $0
Q4 2021 Jan 06, 2022	BUY	$63.34 - $74.11 $4,307 - $5,039	68 New	68 $5,000
Q1 2021 Apr 27, 2021	SELL	$76.02 - $100.5 $2,052 - $2,713	-27 Closed	0 $0
Q3 2020 Oct 22, 2020	BUY	$85.07 - $109.69 $2,296 - $2,961	27 New	27 $2,000
Q1 2020 Apr 30, 2020	SELL	$63.18 - $85.97 $379 - $515	-6 Closed	0 $0
Q4 2019 Jan 31, 2020	SELL	$73.04 - $95.72 $730 - $957	-10 Reduced 62.5%	6 $1,000
Q3 2019 Oct 25, 2019	BUY	$72.82 - $86.52 $436 - $519	6 Added 60.0%	16 $1,000
Q2 2019 Aug 02, 2019	SELL	$73.52 - $88.7 $367 - $443	-5 Reduced 33.33%	10 $1,000
Q1 2019 Apr 24, 2019	BUY	$63.56 - $88.17 $317 - $440	5 Added 50.0%	15 $1,000
Q4 2018 Feb 01, 2019	SELL	$58.5 - $69.94 $1,579 - $1,888	-27 Reduced 72.97%	10 $1,000
Q2 2018 Jul 31, 2018	BUY	$60.85 - $83.98 $608 - $839	10 Added 37.04%	37 $2,000
Q1 2018 Apr 25, 2018	BUY	$83.06 - $100.98 $166 - $201	2 Added 8.0%	27 $2,000
Q4 2017 Jan 29, 2018	SELL	$93.56 - $116.6 $3,742 - $4,664	-40 Reduced 61.54%	25 $2,000
Q3 2017 Oct 19, 2017	BUY	$109.15 - $138.27 $7,094 - $8,987	65	65 $8,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Tarbox Family Office, Inc., based on Form 13F filings with the SEC.

Stay updated on Tarbox Family Office, Inc. with notifications on news.